Skip to search formSkip to main contentSkip to account menu

CEP-18770

Known as: CEP 18770, Proteasome Inhibitor CEP 18770 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

delanzomib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity
2017
2017
Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway
Cervical cancer, the third most commonly occurring cancer, is the second leading cause of cancer related mortality among women… 
2016
2016
Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions
PurposeIschemic acute kidney injury is characterized by apoptosis of tubular epithelial cells. Proteasome plays a key role in… 
Review
2013
Review
2013
Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress… 
Review
2013
Review
2013
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
2012
2012
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Highly Cited
2010
Highly Cited
2010
The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan
The anti‐multiple myeloma (MM) efficacy of bortezomib has led to the development of other proteasome inhibitors (PI), including… 
2010
2010
Efficacy and Tolerability of CEP-18770 in Combination with Dexamethasone and Lenalidomide Using a SCID-Hu Model of Multiple Myeloma (MM)
Abstract 2946 Introduction: We previously demonstrated the anti-MM effects of the proteasome inhibitor (PI) CEP-18770 with… 
2009
2009
Oral Dosing of the Novel Proteasome Inhibitor CEP-18770 Shows Marked Anti-Myeloma Effects in SCID-Hu Models of Multiple Myeloma.
Abstract 1840 Poster Board I-866 Introduction: Currently, there is no orally administered proteasome inhibitor (PI) which has… 
2008
2008
The Novel Proteasome Inhibitor CEP-18770 Inhibits Myeloma Tumor Growth In Vitro and In Vivo and Enhances the Anti-MM Effects of Melphalan
Proteasome inhibitors (PI) have been shown to be effective agents for the treatment of multiple myeloma (MM) and enhance the anti… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)